博纳西亚递表港交所主板

Group 1 - The core viewpoint of the article is that Bonasia (Hangzhou) Pharmaceutical Technology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with the aim of enhancing its capital for growth in the clinical research sector [1] - Bonasia is a clinical contract research organization (CRO) based in Hangzhou, China, focusing on digital empowerment to innovate clinical research for new drugs [1] - The company's primary business involves providing clinical trial technical services to domestic and international pharmaceutical and biotechnology companies, aiming to accelerate the research and commercialization processes of chemical drugs and biological products [1]